Published in J Fam Pract on February 01, 1979
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils. J Clin Invest (1975) 3.39
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 3.34
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol (1984) 2.76
Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun (1985) 2.75
Regulation of methionine synthesis in Salmonella typhimurium: mutants resistant to inhibition by analogues of methionine. Genetics (1968) 2.62
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Strand-selective repair of DNA damage in the yeast GAL7 gene requires RNA polymerase II. J Biol Chem (1992) 1.94
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun (1986) 1.90
Familial dementia caused by polymerization of mutant neuroserpin. Nature (1999) 1.88
Further study of beta-TGFs released by virally transformed and non-transformed cells. Int J Cancer (1985) 1.77
Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J (1995) 1.73
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Preferential repair of DNA damage on the transcribed strand of the human metallothionein genes requires RNA polymerase II. Mutat Res (1991) 1.58
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F. Cancer Res (1984) 1.51
The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost (2011) 1.51
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum (1990) 1.50
Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem (1997) 1.47
Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study. Arthritis Rheum (1995) 1.44
Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem (1998) 1.42
Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem (2000) 1.40
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure (1999) 1.40
Cytophilic properties of IgA to human neutrophils. Adv Exp Med Biol (1974) 1.38
Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol (1989) 1.38
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res (1994) 1.36
Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol (1995) 1.23
Characterization of an IgE receptor isolated from cultured B-type lymphoblastoid cells. J Immunol (1978) 1.23
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost (2006) 1.21
Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol (1996) 1.17
Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol (1999) 1.16
A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem (1995) 1.16
Regulation of the methionine-specific aspartokinase and homoserine dehydrogenase of Salmonella typhimurium. J Gen Microbiol (1968) 1.13
Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol (2000) 1.08
2,4-Dinitrophenyl receptors on mouse thymus and spleen cells. J Exp Med (1973) 1.07
Stimulation of murine lymphocyte responses by cations. Cell Immunol (1986) 1.06
Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum (1995) 1.06
Acidic cellular environments: activation of latent TGF-beta and sensitization of cellular responses to TGF-beta and EGF. Int J Cancer (1989) 1.05
Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem (1992) 1.05
Susceptibility of C5-deficient mice to listeriosis: modulation by Concanavalin A. Cell Immunol (1978) 1.04
Identification and activation of latent transforming growth factor beta. Methods Enzymol (1991) 1.04
Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry (1986) 1.04
Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation (2001) 1.04
Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab (1980) 1.03
Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J Biol Chem (1995) 1.02
Regulation of the methionine feedback-sensitive enzyme in mutants of Salmonella typhimurium. J Bacteriol (1972) 1.01
Alteration of transforming growth factor-beta1 response involves down-regulation of Smad3 signaling in myofibroblasts from skin fibrosis. Am J Pathol (2001) 0.99
The serpin-proteinase complex revealed. Nat Struct Biol (1997) 0.96
Level of methionyl-tRNA synthetase in merodiploids of Escherichia coli K12. Eur J Biochem (1970) 0.94
Measurement of macrophage adherence and spreading with weak electric fields. J Immunol Methods (1990) 0.94
In vivo the environmental pollutants lead and mercury induce oligoclonal T cell responses skewed toward type-2 reactivities. Cell Immunol (1997) 0.94
Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer (1997) 0.94
A histological comparison of adenomatous and hyperplastic parathyroid glands. J Clin Pathol (1978) 0.93
Serpin conformational change in ovalbumin. Enhanced reactive center loop insertion through hinge region mutations. Biochemistry (1997) 0.93
Cells transformed by Rous sarcoma virus release transforming growth factors. J Cell Physiol (1982) 0.93
New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environ Health Perspect (1999) 0.92
Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost (2010) 0.92
Metal-induced modulation of nitric oxide production in vitro by murine macrophages: lead, nickel, and cobalt utilize different mechanisms. Toxicol Appl Pharmacol (1996) 0.92
Lead potentiates cytokine- and glutamate-mediated increases in permeability of the blood-brain barrier. Neurotoxicology (1998) 0.91
Differential effects of concanavalin A and phytohemagglutinin on murine immunity. Suppression and enhancement of humoral immunity. Cell Immunol (1977) 0.91
Differential in vitro effects of physiological and atmospheric oxygen tension on normal human peripheral blood mononuclear cell proliferation, cytokine and immunoglobulin production. Int J Immunopharmacol (1996) 0.91
Mechanisms for the cytotoxicity of cysteamine. Toxicol Sci (2001) 0.89
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res (2012) 0.89
Sarcoidosis associated with Crohn's disease of ileum, mouth and oesophagus. J R Soc Med (1983) 0.89
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int (2006) 0.89
Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost (2004) 0.89
Modulation of T-cell functions. I. Effect of 2-mercaptoethanol and macrophages on T-cell proliferation. Cell Immunol (1980) 0.89
Heavy metal modulation of lymphocyte activities. 1. In vitro effects of heavy metals on primary humoral immune responses. Toxicol Appl Pharmacol (1981) 0.89
The efficiency of maternal transfer of lead and its influence on plasma IgE and splenic cellularity of mice. Toxicol Sci (2000) 0.88
Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest (1995) 0.88
Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem (1993) 0.88
The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1' methionine. J Biol Chem (1991) 0.87
Reduced glutathione is highly expressed in white matter and neurons in the unperturbed mouse brain--implications for oxidative stress associated with neurodegeneration. Brain Res (2009) 0.87
Determination of glutathione in lymphocytes and possible association of redox state and proliferative capacity of lymphocytes. Biochem J (1981) 0.87
Growth stimulation of murine fibroblasts by TGF-beta1 depends on the expression of a functional p53 protein. Oncogene (1999) 0.87
The heavy metal lead exhibits B cell-stimulatory factor activity by enhancing B cell Ia expression and differentiation. J Immunol (1990) 0.87
Differential effects of lead and cAMP on development and activities of Th1- and Th2-lymphocytes. Toxicol Sci (1998) 0.87
Suppression of methionyl transfer RNA synthetase mutants of Salmonella typhimurium by methionine regulatory mutations. J Gen Microbiol (1970) 0.87
Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J Biol Chem (1995) 0.87
Differences in the occurrence of hypertension among (NZB X NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol (1984) 0.87
Fluorometric quantitation of cellular and nonprotein thiols. Anal Biochem (1986) 0.87
Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem (1996) 0.86
Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med (1998) 0.86
Lead, a major environmental pollutant, is immunomodulatory by its differential effects on CD4+ T cells subsets. Toxicol Appl Pharmacol (1991) 0.86
Interleukin-12 promotes enhanced resistance to Listeria monocytogenes infection of lead-exposed mice. Toxicol Appl Pharmacol (1997) 0.86
Immunomodulation by metals. Fundam Appl Toxicol (1994) 0.86
Effect of lead on macrophage function. J Leukoc Biol (1988) 0.86
Neuronal cell death and reactive oxygen species. Cell Mol Neurobiol (2000) 0.86
Modulation of T-cell function. II. Chemical basis for the involvement of cell surface thiol-reactive sites in control of T-cell proliferation. Cell Immunol (1981) 0.85
The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A. J Biol Chem (1995) 0.85
Murine T-cell preparations: radiosensitivity of helper activity. Cell Immunol (1978) 0.85
The spatial coding strategies of one-year-old infants in a locomotor search task. Child Dev (1995) 0.84
Lead inhibits nitric oxide production in vitro by murine splenic macrophages. Toxicol Appl Pharmacol (1995) 0.84
Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem (2000) 0.84